@article {20374,
	title = {Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients},
	journal = {J Antimicrob ChemotherJ Antimicrob ChemotherJ Antimicrob Chemother},
	volume = {74},
	number = {3},
	year = {2019},
	note = {1460-2091Soulie, CathiaSantoro, Maria MercedesCharpentier, CharlotteStorto, AlexandreParaskevis, DimitriosDi Carlo, DomenicoGennari, WilliamSterrantino, GaetanaZazzi, MaurizioPerno, Carlo FedericoCalvez, VincentDescamps, DianeCeccherini-Silberstein, FrancescaMarcelin, Anne-Genevi{\`e}veJournal ArticleResearch Support, Non-U.S. Gov{\textquoteright}tEnglandJ Antimicrob Chemother. 2019 Mar 1;74(3):614-617. doi: 10.1093/jac/dky464.},
	month = {Mar 1},
	pages = {614-617},
	edition = {2018/11/27},
	abstract = {BACKGROUND: Doravirine is a novel HIV-1 NNRTI recently shown to be non-inferior to both darunavir/ritonavir and efavirenz in combination therapy with two NRTIs in treatment-naive patients. Doravirine has an in vitro resistance profile that is distinct from other NNRTIs and retains activity against viruses containing the most frequently transmitted NNRTI mutations. OBJECTIVES: The aim of this study was to examine the prevalence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients in Europe. METHODS: From 2010 to 2016, 9764 treatment-naive patients were tested for NNRTI antiretroviral drug resistance by bulk sequencing in Greece, Italy and France. We studied the prevalence of doravirine resistance-associated mutations previously identified in vitro: V106A/M, V108I, Y188L, V190S, H221Y, F227C/L/V, M230I/L, L234I, P236L, Y318F and K103N/Y181C. RESULTS: Among 9764 sequences, 53.0\% and 47.0\% of patients had B and non-B subtypes, respectively. Overall, the presence of at least one doravirine resistance-associated mutation (n = 137; 1.4\%) or the K103N/Y181C mutations (n = 5; 0.05\%) was very rare. The most prevalent mutations were V108I (n = 62; 0.6\%), Y188L (n = 18; 0.2\%), H221Y (n = 18; 0.2\%) and Y318F (n = 23; 0.2\%). The frequency of doravirine resistance-associated mutations was similar between B and non-B subtypes. In comparison, the prevalence of rilpivirine, etravirine, nevirapine and efavirenz resistance was higher whatever algorithm was used (ANRS: 8.5\%, 8.1\%, 8.3\% and 3.9\%, respectively; Stanford: 9.9\%, 10.0\%, 7.5\% and 9.4\%, respectively). CONCLUSIONS: The prevalence of doravirine resistance-associated mutations is very low in antiretroviral-naive patients. These results are very reassuring for doravirine use in naive patients.},
	keywords = {*Drug Resistance, Viral, Anti-HIV Agents/*pharmacology, France, Gene Frequency, Greece, HIV Infections/*virology, HIV-1/*drug effects/*genetics/isolation \& purification, Humans, Italy, Mutation, Missense, Prevalence, Pyridones/*pharmacology, Triazoles/*pharmacology},
	isbn = {0305-7453},
	author = {Soulie, C. and Santoro, M. M. and Charpentier, C. and Storto, A and Paraskevis, D and Di Carlo, D. and Gennari, W. and Sterrantino, G. and Zazzi, M and Perno, C. F. and Calvez, V. and Descamps, D and Ceccherini-Silberstein, F. and Marcelin, A. G.}
}
